Patents matching “antagonist”

US 7803560

Methods of screening for antagonists of mammalian monocyte chemoattractant protein receptors

The Regents of the University of California · Granted Sep 28, 2010 · Expires Sep 23, 2030

US 7803812

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Sep 28, 2010 · Expires Sep 23, 2030

US 7799789

Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity

Pharmacopeia Drug Discovery, Inc. · Granted Sep 21, 2010 · Expires Sep 16, 2030

US 7795267

Bicyclic piperazine compound having TGR23 antagonistic activity

Takeda Pharmaceutical Company Limited · Granted Sep 14, 2010 · Expires Sep 9, 2030

US 7790728

Pyrazine derivatives useful as adenosine receptor antagonists

Laboratories Almirall, S.A. · Granted Sep 7, 2010 · Expires Sep 2, 2030

US 7776879

Quinuclidine carbamate derivatives and their use as M3 antagonists

Almirall, S.A. · Granted Aug 17, 2010 · Expires Aug 12, 2030

US 7759335

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrm Discovery, Inc. · Granted Jul 20, 2010 · Expires Jul 15, 2030

US 7754206

Method for treating cancer using a Notch4 ligand antagonist

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 13, 2010 · Expires Jul 8, 2030

US 7731953

Methods for use of TSLP and agonists and antagonists thereof

The United States of America, as represented by the Department of Health and Human Services · Granted Jun 8, 2010 · Expires Jun 3, 2030

US 7728144

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jun 1, 2010 · Expires May 27, 2030

US 7700547

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted Apr 20, 2010 · Expires Apr 15, 2030

US 7691878

Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance, Inc. · Granted Apr 6, 2010 · Expires Apr 1, 2030

US 7687519

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Mar 30, 2010 · Expires Mar 25, 2030

US 7687521

Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Theravance, Inc. · Granted Mar 30, 2010 · Expires Mar 25, 2030

US 7687481

Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

Jenrin Discovery, LLC · Granted Mar 30, 2010 · Expires Mar 25, 2030

US 7683173

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Mar 23, 2010 · Expires Mar 18, 2030

US 7666889

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Feb 23, 2010 · Expires Feb 18, 2030

US 7662365

Polymer conjugates of opioid antagonists

Nektar Therapeutics · Granted Feb 16, 2010 · Expires Feb 11, 2030

US 7659403

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Feb 9, 2010 · Expires Feb 4, 2030

US 7655685

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Feb 2, 2010 · Expires Jan 28, 2030

US 7655758

Stable liquid IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Feb 2, 2010 · Expires Jan 28, 2030

US 7652035

CRF receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jan 26, 2010 · Expires Jan 21, 2030

US 7642355

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jan 5, 2010 · Expires Dec 31, 2029

US 7632847

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Dec 15, 2009 · Expires Dec 10, 2029